Edwards Lifesciences Corp
Statements
Segments
US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Edwards Lifesciences Corp (EW). It shows which part of the business is growing — and which one is holding it back.
Revenue by business segment
| Segment | 2020 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| United States | $2.52B 57.7% | $2.63B 58.9% · +4.4% | $2.95B 58.8% · +12.2% | $3.21B 58.9% · +8.8% | $3.54B 58.4% · +10.5% |
| Europe | $945.2M 21.7% | $1.04B 23.3% · +10.1% | $1.18B 23.6% · +13.4% | $1.32B 24.3% · +12.0% | $1.52B 25.0% · +14.8% |
| Rest of World | $451.5M 10.4% | $436.0M 9.8% · -3.4% | $531.1M 10.6% · +21.8% | $572.0M 10.5% · +7.7% | $652.3M 10.8% · +14.0% |
| Japan | $448.6M 10.3% | $359.5M 8.1% · -19.9% | $350.8M 7.0% · -2.4% | $339.8M 6.2% · -3.1% | $354.7M 5.8% · +4.4% |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Revenue by region
| Segment | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| United States | $2.52B 57.4% | $2.96B 56.6% · +17.7% | $3.13B 58.2% · +5.7% | $3.51B 58.4% · +12.0% |
| Europe | $973.6M 22.2% | $1.19B 22.7% · +22.3% | $1.17B 21.8% · -1.3% | $1.33B 22.2% · +13.6% |
| Rest of World | $435.8M 9.9% | $550.2M 10.5% · +26.3% | $601.4M 11.2% · +9.3% | $709.2M 11.8% · +17.9% |
| Japan | $460.1M 10.5% | $528.9M 10.1% · +15.0% | $473.6M 8.8% · -10.5% | $452.4M 7.5% · -4.5% |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Revenue by product line
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Transcatheter Aortic Valve Replacement | $2.86B 65.1% | $3.42B 65.4% · +19.8% | $3.52B 78.8% · +2.8% | $3.88B 77.4% · +10.3% | $4.11B 75.5% · +5.8% | $4.49B 74.0% · +9.3% |
| Surgical Structural Heart | $761.8M 17.4% | $889.1M 17.0% · +16.7% | $829.7M 18.6% · -6.7% | $932.6M 18.6% · +12.4% | $981.3M 18.0% · +5.2% | $1.03B 17.0% · +4.9% |
| Transcatheter Mitral and Tricuspid Therapies | $41.8M 1.0% | $86.0M 1.6% · +105.7% | $116.1M 2.6% · +35.0% | $197.6M 3.9% · +70.2% | $352.1M 6.5% · +78.2% | $550.6M 9.1% · +56.4% |
| Critical Care | $725.4M 16.5% | $834.9M 16.0% · +15.1% | – | – | – | – |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.
Data as of: August 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.